Abstract: Embodiments of the present disclosure provide compositions comprising compounds useful to make radiotracers for positron emission tomography imaging, as well as methods for making and using these compositions.

Abstract: Embodiments of the present disclosure provide compositions and methods for performing positron emission tomography (PET) and, more particularly, to compositions and methods for the development and use of 18F-based PET tracers for use in selected imaging techniques such as studies of agents selected to modulate adipose tissue physiology.

Abstract: Embodiments of the present disclosure provide compositions and methods for performing positron emission tomography (PET) and, more particularly, to compositions and methods for the development and use of 18F-based PET tracers for use in selected imaging techniques such as studies of myocardial physiology. In particular, as disclosed herein, at tracer levels, [18F]F—AraG has the ability to be used in a number of new PET methodologies including those designed for cardiac and/or mitochondrial activity imaging. The use of [18F]F—AraG as a PET tracer offers significant advantages over conventional 18F labeled tracers in a number of distinct applications including observations of selected physiological phenomena such as myocardial perfusion, myocardial viability, and heart inflammation. Methods of the invention include those designed to use [18F]F—AraG to observe patient physiological responses to various therapeutic agents, as well as using [18F]F—AraG as a PET tracer in drug development studies.

Abstract: Embodiments of the present disclosure provide compositions comprising compounds useful to make radiotracers for positron emission tomography imaging, as well as methods for making and using these compositions.